Novozymes As B Stock Ten Year Return
| NVZMF Stock | USD 58.80 0.24 0.41% |
Novozymes AS B fundamentals help investors to digest information that contributes to Novozymes A/S's financial success or failures. It also enables traders to predict the movement of Novozymes Pink Sheet. The fundamental analysis module provides a way to measure Novozymes A/S's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novozymes A/S pink sheet.
Novozymes |
Novozymes AS B Company Ten Year Return Analysis
Novozymes A/S's Ten Year Return shows the total annualized return generated from holding a fund for the last 10 years and represents fund's capital appreciation, including dividends losses and capital gains distributions. This return indicator is considered by many investors to be the ultimate measures of fund performance and can reflect the overall performance of the market or market segment it invests in.
More About Ten Year Return | All Equity Analysis
Ten Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Ten Year Fund Return indicator can give a sense of overall fund long-term potential, it is recommended to compare funds performances against other similar funds or market benchmarks for the same 10-year interval.
| Competition |
Based on the latest financial disclosure, Novozymes AS B has a Ten Year Return of 0.0%. This indicator is about the same for the Basic Materials average (which is currently at 0.0) sector and about the same as Specialty Chemicals (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Novozymes Ten Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novozymes A/S's direct or indirect competition against its Ten Year Return to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novozymes A/S could also be used in its relative valuation, which is a method of valuing Novozymes A/S by comparing valuation metrics of similar companies.Novozymes is currently under evaluation in ten year return category among its peers.
Novozymes Fundamentals
| Return On Equity | 0.28 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 14.47 B | |||
| Shares Outstanding | 222.86 M | |||
| Shares Owned By Insiders | 8.04 % | |||
| Shares Owned By Institutions | 42.30 % | |||
| Price To Earning | 33.38 X | |||
| Price To Book | 6.19 X | |||
| Price To Sales | 0.82 X | |||
| Revenue | 17.55 B | |||
| Gross Profit | 9.59 B | |||
| EBITDA | 6.12 B | |||
| Net Income | 3.68 B | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 3.67 X | |||
| Total Debt | 7.31 B | |||
| Debt To Equity | 0.58 % | |||
| Current Ratio | 1.20 X | |||
| Book Value Per Share | 50.02 X | |||
| Cash Flow From Operations | 4.01 B | |||
| Earnings Per Share | 1.90 X | |||
| Price To Earnings To Growth | 3.85 X | |||
| Target Price | 28.3 | |||
| Number Of Employees | 6.44 K | |||
| Beta | 0.4 | |||
| Market Capitalization | 13.95 B | |||
| Total Asset | 27.98 B | |||
| Retained Earnings | 9.99 B | |||
| Working Capital | 2.67 B | |||
| Current Asset | 6.08 B | |||
| Current Liabilities | 3.41 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.38 % | |||
| Net Asset | 27.98 B | |||
| Last Dividend Paid | 6.0 |
About Novozymes A/S Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novozymes AS B's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novozymes A/S using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novozymes AS B based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Novozymes Pink Sheet
Novozymes A/S financial ratios help investors to determine whether Novozymes Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novozymes with respect to the benefits of owning Novozymes A/S security.